Establishing a <i>CYP3A5</i> genotype–guided tacrolimus dosing protocol in adult kidney transplant recipients
Implementation of CYP3A5 genotype-guided tacrolimus dosing requires unique considerations associated with route of administration and transplant population, but integrating pharmacogenetics into a tacrolimus dosing protocol is feasible with multidisciplinary support. Future studies will evaluate the impact of this dosing strategy on clinical and healthcare utilization outcomes.
Authors
- Christopher Zimmerman
- Amy L. Pasternak (ORCID: https://orcid.org/0000-0002-3162-5498)
- Jeong Mi Park (ORCID: https://orcid.org/0000-0002-7961-494X)
Institutions
- University of Michigan (US)
- VA Ann Arbor Healthcare System (US)
- Michigan Medicine (US)
Publication Details
- Journal
- American Journal of Health-System Pharmacy
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1093/ajhp/zxaf215
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00